Anocca’s Post

Leverage your external team to bring new tools for this stage of the race. With PEDAL, your drug discovery program can leverage characterized tumor samples, including PI3K and KRAS biomarker data. Find out how PEDAL can help your program move ahead of the pack and lead with a higher probability of success.       https://lnkd.in/ghYNHe8v     #drugdiscovery #drugdevelopment #pharma #emergingtechnologies #biopharma #molecularbiology #oncologydrugdiscovery #oncology #machinelearning #AI  #marketaccess #artificialintelligence #cancerresearch #biotech #lifesciences 

Gain insightful data to support your oncology program by understanding how heterogeneous tumors respond to your drug. Powerful information to design successful clinical trials.

Antibody-drug conjugates (ADCs) deliver highly-potent drug payloads to precisely kill cancer cells. In our Piper Sandler BioInsights deep-dive report “Antibody-Drug Conjugates – Top1 of Mind,” senior biotech research analysts Joseph Catanzaro, Chris Raymond, Allison Bratzel, CFA and Ted Tenthoff share their analysis of the progress, innovation and opportunity in this rapidly-emerging field.         #PSCbioinsights #biotech #oncology #biopharma #ADCs #bioinsights

Predicting outcomes in #Oncology drug development isn't rocket science - it's just science! 🚀 In silico modelling of human trials is a powerful tool to predict outcomes in #oncology drug development…. but it’s important to tread carefully when interpreting the results. 💡 The key? Start with an established model of treatment and tumour characteristics. 🔑 Our Virtual Tumour™ platform is one of the industry’s most advanced predictive models focused solely on oncology. Our model is calibrated using available PK and PD data and can predict the effect on tumour growth of combinations of anti-cancer agents, including radiation. 🔬 Curious about how Physiomics plc uses our Virtual Tumour™ platform and custom models to support drug development? Let's chat! #DrugDevelopment #InSilicoModeling #ClinicalTrials #PKPDModelling #VirtualTumour #Data-DrivenDecisions #BioTech #Pharma

#Ariceum is pleased to announce that it will be presenting new #radioligand therapy data at the American Association for Cancer Research (#AACR) Annual Meeting 2024 in San Diego, California, from 5-10 April, 2024.   Join Anika Jäkel, Senior Director, Head of Translational Biology and Non-Clinical Pharmacology at #Ariceum on 9 April when she will present a poster demonstrating new findings on the discovery of novel macrocyclic peptide radioligands for tumor therapy by mRNA display in collaboration with research partner, UCB.   We look forward to sharing insights and connecting at #AACR2024. Learn more about the data in the press release in the comments below!   #lifesciences #biotech #radiopharmaceuticals #satoreotide #ATT001 #ATT002

Oncofactory, now part of ERBC (European Research Biology Center) group, offers a unique technology platform with a core process for generating patient tumor replicas in #avian embryos (AVI-PDX™) perfectly suited for the evaluation of #anticancer therapies. Our AVI-PDX model gives you access to direct #invivo evaluation of your molecules in patient tumor samples. You can determine in few days the efficacy of cancer treatments on human tumor cells transplanted into the avian embryo from a statistically significant number of eggs. 👉Contact us to book a meeting with our team to discuss your project: contact@oncofactory.com To learn more, join the upcoming webinar series on September 7. ➡️ https://lnkd.in/e9rJWMFA #PDXmodel #oncology #drugdevelopment #nonclinical #clinicaltrials #personalizedmedicine #3Rs #ethical #NAM

Radiopharmaceuticals are leading the way in how #oncology patients are being diagnosed and treated. In this episode of Biotech Breakthroughs, Tim Lugo is joined by equity analysts Andy Hsieh and Alexandra Ramsey, Ph.D. to examine why radioisotope #innovation may revolutionize treatment for millions of people in the coming years. Listen now: https://lnkd.in/epPkafDQ #biotech #WilliamBlairThinking

Your drug development program will gain a competitive advantage to get the best medicine for the right patient fastest to market with PEDAL. Leverage 100s of characterized tumor samples, including biomarkers for PI3K and KRAS, to move your program ahead of the pack and lead with a higher probability of clinical success. Partner with Predictive Oncology to design a PEDAL campaign customized to generate actionable data that will drive the strongest program forward. https://lnkd.in/ghYNHe8v #drugdiscovery #drugdevelopment #pharma #emergingtechnologies #biopharma #molecularbiology #oncologydrugdiscovery #oncology #machinelearning #AI  #marketaccess #artificialintelligence #cancerresearch #biotech #lifesciences

John Catanzaro discusses the history behind PBIMA Precision Based Immuno – Molecular Augmentation) reviewing the different generations behind the platform development.   Our leader at Neo7Bioscience, CEO and Co- Founder John Catanzaro, is dedicated to advancing medicine. In addition to his role at Neo7Bioscience, he is also the Chief Product Developer with SpacePharma.   Currently Neo7Bioscience is working on Generation 4 of the PBIMA platform. In addition to this Neo7Bioscience is in works with SpacePharma to advance drug discovery. The future of medicine is now. #drugdiscovery #drugdevelopment #peptides #peptide #engineering #translation #transcription #unpredictable #polypeptides #dna #rna #aging #longevity #cancer #beatcancer #cancerawareness #limedisease #neurodegenerative #immunotherapy #autoimmune #longevity #AI #artificialinteligence #deepmachinelearning

We are thrilled to have entered into a license and option agreement with Janssen Inc. (“Janssen”), a Johnson & Johnson company, that focuses on one of the most exciting areas of development in #oncology: armoring CAR T cells to secrete IL-18. Under the terms of the agreement, Janssen will develop, manufacture, and commercialize select CAR T-based cell therapy candidates armored with our novel proprietary decoy-resistant IL-18. Early research in this area has generated very exciting results that have attracted a growing amount of activity by multiple parties. We look to build on these promising #data and seek to harness the potential of enhancing #CART cell therapy with best-in-class IL-18 biology. Read the full press release: https://lnkd.in/gEBSdi2e